Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Hear the Holidays: Ways to Help People with Hearing Loss Enjoy the Holidays

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/yQwa2WRw59E The holidays are a time to share special moments with loved ones and celebrate those relationships, but if you have hearing loss and are struggling to hear or follow conversations, you may feel disconnected from family and friends this holiday season. Often, feelings of embarrassment or frustration can cause individuals with hearing loss to stop socializing or participating in events or activities that they used to enjoy. According to a HearingLife and Harris Poll survey, 72% of people with hearing loss wish their hearing was better to enjoy holiday and special gatherings*. HearingLife is celebrating the holiday season with the “Hear the Magic. Love Your Ears” holiday campaign accompanied by the second annual “Magic of Giving Back” program aimed to help those with hearing loss gain back the joyful sounds of the holiday season. "We understand the challenges that come with hearing loss, such as difficulty following conversations and feeling embarrassed," said Dr. Leslie Soiles, Chief Audiologist, HearingLife. "At HearingLife, we believe everyone deserves to hear their favorite sounds of the season and we want to help those in need regain their confidence and enjoy connecting with loved ones during the holiday season." For the opportunity to receive free hearing aids through the “Magic of Giving Back,” people can submit either a personal story, or a story on behalf of a loved one, explaining why they are a candidate for the gift of hearing. To learn more and share your story, visit www.HearingLife.com/Magic by November 12th About HearingLife: HearingLife is a national hearing care company and part of the Demant Group, a global leader in hearing healthcare built on a heritage of care, health, and innovation since 1904. HearingLife operates nearly 700 hearing care centers across 42 states. We follow a scientific, results-oriented approach to hearing healthcare that is provided by highly skilled and caring professionals. Our vision is to help more people hear better through life-changing hearing health delivered by the best personalized care. To learn more, visit: https://www.hearinglife.com. *Survey Method: This survey was conducted online within the United States by The Harris Poll on behalf of HearingLife from August 19-23, 2021, among 2,044 adults ages 18+, among whom 253 have hearing loss. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact hearinglife@kaplow.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 10, 2022 04:00 PM Eastern Standard Time

Video

Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

Organicell Regenerative Medicine, Inc.

Learn more about Organicell Regenerative Medicine, Inc.from this latest report. During the peak of the deadly COVID-19 pandemic, one novel therapeutic that seems to have played an important role in helping save lives was Organicell Regenerative Medicine Inc. ’s (OTCMKTS: OCEL) Zofin™. Even though COVID-19 therapies and vaccines have been dominated by big players like BioNTech SE — ADR (NASDAQ: BNTX), Johnson & Johnson (NYSE: JNJ), Moderna Inc. (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), the U.S. Food and Drug Administration (FDA) approved Zofin™ to be used for patients — some whose conditions were serious and life-threatening. The company hit a significant milestone in October 2020 when the FDA granted expanded access for patients to be treated with their flagship therapeutic, Zofin™. The FDA gave Emergency Investigational New Drug (eIND) approval for treating COVID-19. The investigational product was used for patients with mild to moderate COVID-19 or who were judged to be at high risk of progression to moderate disease. Zofin™, manufactured to retain naturally occurring microRNAs without adding any other substance or diluent, was reportedly among the first reported acellular therapies accessed under the FDA’s approved expanded access program. The FDA approval followed the treatment of six outpatients treated under investigational new drugs (INDs) status with Zofin™. Organicell reported chalking up another win when in May 2021, the Drug Regulatory Authority of Pakistan approved Zofin™ for use with patients on compassionate grounds following the patient’s COVID-19 diagnosis and admittance to an intensive care unit for treatment on a ventilator. These huge stamps of approvals from major regulatory authorities seem to have put the spotlight on Organicell, indicating that it could be doing something extraordinary and is a company to watch. The devastating impact of the COVID-19 pandemic on humanity and the global economy has triggered a sudden wake-up call for an all-hands-on-deck approach to developing vaccines and therapies to shore up humanity’s immunity against present and future viruses. Companies like Organicell could play a key role. For most investors, identifying publicly-traded companies like Organicell with the most promising prospects for converting research and development initiatives into commercial remedies could pay off. What Makes Organicell Different? Based in Nova Southeastern University’s (NSU) Center for Collaborative Research, Organicell is a clinical-stage research company with a mission to be the first company to prove the efficacy of extracellular vesicles (EVs) — also known as exosomes — in clinical trials for several conditions. The fully integrated clinical-stage biotechnology company says it is committed to researching, developing and manufacturing new biologic medicine, focusing on current and potential regenerative therapeutics. Comprised of two arms — clinical research and commercial — Organicell generates revenue by extracting and delivering potent formulas of EVs for topical, skincare applications. The company reports that its proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, growth factors, and key proteins without adding or combining any other substance or diluent. Zofin™ Organicell is actively investigating the therapeutic safety and efficacy of Zofin™ in subjects with various stages of COVID-19 infection — mild to moderate, moderate to severe, and post-COVID-19 complications a.k.a Long Haulers. Through the FDA’s single-patient emergency and compassionate use mechanism, Organicell has treated 18 subjects to observe Zofin™ safety while secondarily observing clinical improvements. Zofin™ was administered intravenously to these patients, who were followed for 28 days post-therapy. Under expanded access, Zofin™ has been administered to patients with mild to moderate COVID-19 infections. These studies demonstrate the first use of a human perinatal-derived nanoparticle biologic as a safe and potentially efficacious treatment for acute respiratory distress syndrome induced by COVID-19 infection. Cheaper And Easier Clinical Trials? According to Organicell, Zofin™ is naturally derived and, therefore, only requires 30 patients to complete Phase I/II trials of clinical trials. Phase III trials should require only 250-300 patients, while clinical trials are currently enrolling and anticipated to be completed within 24 months. Clinical trials are a crucial element of the drug development process, but they are often expensive, with costs running into hundreds of millions of dollars. Organicell says its trials are cheaper and faster than those of other companies. The company reports that the cost per trial is approximately $10 million with only 250-350 patients needed, compared to others that cost hundreds of millions of dollars and involve more patients. “When people hear about clinical trials, they immediately get spooked because they think hundreds of millions of dollars and tens of thousands of patients,” Organicell’s President and Acting CEO Matt Sinnreich told Benzinga. “Since we are a biologic, we have a much smaller requirement.” With an entire clinical trial costing about $10 million, Sinnreich believes the company is “well positioned to get Phase I / Phase II enrolled and has a board of directors that can help with additional funding needs.” Apart from Zofin™, Organicell is also working on PPX, Factor X, and XoTin. The company says it is looking at health and beauty partnerships, clinical trials to pursue a Biologics License Application (BLA), and evolving the science to address other specific ailments. Unlike other companies that may be spending on speculative research, Organicell says it is already generating revenue with an ultimate goal to uplist soon. Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/

November 10, 2022 02:17 PM Eastern Standard Time

Dynamic Works Institute to Launch CWDP Recertification Package at NAWDP Youth Symposium

Dynamic Works Institute

Dynamic Works Institute, a leading provider of transformative training for individuals, corporations and community-based organizations, will introduce its new Certified Workforce Development Professional (CWDP) Recertification Package at the National Association of Workforce Development Professionals (NAWDP) 2022 Youth Symposium, booth 211. The show will take place from November 14-16 at The Westin Charlotte (Charlotte, N.C.). Achieving CWDP certification demonstrates that a workforce development professional has completed the required training In order to maintain their CWDP certification, workforce development professionals must complete at least 60 hours of professional development related to one or more of the five competencies identified by NAWDP, which include: Customer Service Methodology, Diversity in Workforce Development, Labor Market Information and Intelligence, Principles of Communication, and Workforce Development Structure, Policies and Programs. The new CWDP Recertification Package from Dynamic Works Institute is specifically designed and delivered by workforce training experts to accommodate the schedules of busy professionals who wish to recertify for their CWDP certification. The Recertification Package includes a selection of live and asynchronous online course options covering all five core competencies identified by NAWDP, which customers can attend as their schedules allow. “We’re excited to introduce our new CWDP Recertification program, as it addresses an unmet need to help busy workforce development professionals receive the training they need for recertification,” said Paul Dunn, CEO of Dynamic Works Institute. “Our live and asynchronous online courses work with our customers’ busy schedules to build on their current skills and help improve job performance. In addition, they are specifically designed to meet the requirements outlined by NAWDP for CWDP recertification.” Dynamic Works Institute’s new Recertification Package can provide the full 60 hours of instruction required for CWDP recertification or supplement any remaining required hours necessary. Customers can choose from a selection of 30, 15 and 10-hour course options, with packages focused on case management, customer empowerment, working with special populations, and more. In addition, all customers are enrolled in 10 hours of free live training to support their success and build a network of peers. After finishing the course, customers receive their completed NAWDP paperwork and application form available for download and submission. To learn more about Dynamic Works Institute’s new CWDP Recertification Package, stop by booth 211 at the NADWP 2022 Youth Symposium, or visit https://dynamicinstitute.com/. About Dynamic Works Institute Dynamic Works Institute offers over 300 virtual, interactive courses, coaching and live webinars to transform the value and success individuals, corporations and community-based organizations derive from their work. The company’s convenient and relevant virtual training services, complemented with extreme customer service, develop the skills and mindsets that make work life more fulfilling. Contact Details Dynamic Works Institute Gena Leisten +1 513-238-4665 gleisten@dwfs.us O’Keeffe PR Dan O’Keeffe +1 513-221-1526 dan@okeeffepr.com Company Website https://dynamicinstitute.com

November 10, 2022 10:03 AM Eastern Standard Time

McQueen Kalligan Insurance Services Joins AmeriLife & AIMCOR Group as First Affiliate Under New Joint Venture

AmeriLife

AIMCOR Consolidated LLC (“ICON”), a joint venture between AIMCOR Group, LLC (“AIMCOR”) and AmeriLife Group, LLC (“AmeriLife”), announced today that it has acquired brokerage general agency McQueen Kalligan Insurance Services, Inc. Per the agreement, terms of the deal were not disclosed. "We’re very excited to officially join ICON and formalize our partnership with AmeriLife, which will help accelerate our goal of providing best-in-class insurance solutions to our brokers and their clients,” said Tim McQueen, president and CEO of McQueen Kalligan. “This new platform offers us a wide selection of product, technology, and back office support, and will allow us to grow the business while maintaining the service excellence our brokers and advisors have become accustomed to." Founded in 1982 with offices in California and Oregon, McQueen Kalligan started as a small Transamerica general agency and has since evolved into a multi-carrier brokerage general agency (BGA), offering its affiliated agents and advisors a diverse portfolio of life, long-term care, disability, and annuities products from top carriers. McQueen Kalligan is a founding member of AIMCOR Group, and now – under ICON and as an affiliate of AmeriLife – joins a best-in-class distribution network that will help it further its growth goals and expand its reach. With the closing of this deal, Tim McQueen also becomes a principal in ICON and will continue to oversee his affiliated office locations alongside his existing leadership team. In a joint statement, Mike Vietri, Chief Distribution Officer of AmeriLife, and John C. Ziambras, president and CEO of AIMCOR Group, said: “The addition of McQueen Kalligan to ICON represents the start of a fresh, new approach to insurance distribution. We’re thrilled to welcome Tim and his team, and equally as excited to get to work together to help power the next era of the firm’s growth.” “We’re honored to announce McQueen Kalligan Insurance Services as ICON’s inaugural affiliate. Tim McQueen and his team truly epitomize our collective mission and fully embrace our long-term strategy and value proposition,” added Marc Verbos, president of ICON. “I’ve had the pleasure of working alongside Tim and his team for the past eight years, and I know the passion and commitment that they have for supporting their agents and advisors to better protect their clients’ financial futures.” ### About McQueen Kalligan McQueen Kalligan Insurance Services, Inc. is a brokerage general agency (BGA) offering several lines of individual insurance protection. The original agency began in Torrance, Calif., in 1982, and now has locations in San Diego, La Palma, and in Bend, Oregon. McQueen Kalligan’s team members are dedicated to top quality service and problem solving for the financial professionals they work with to provide solutions for business owners, families and estates. For more information, visit MKISInc.com. About ICON ICON (“AIMCOR Consolidated LLC”) is a joint venture between AIMCOR Group, LLC and AmeriLife Group, LLC. By combining the power of a premier national marketing organization (“NMO”) with capital resources, innovative technology, a multi-product platform and a robust suite of centralized shared services, ICON offers brokerage general agencies (BGAs) a different way to stay competitive and evolve their business. ICON helps its partners focus on long-term sustainability by helping reduce risk, gain access to capital, and empower their ability to deliver a comprehensive portfolio of products and services, all while supporting their producers so that they can better scale their business, protect their legacy, and enhance their service offerings. Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com ICON Mike English +1 866-428-0180 mike.english@aimcorgroup.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com

November 10, 2022 09:00 AM Eastern Standard Time

New Report Reveals the Potential Reach of Direct Primary Care to Employers

Nice Healthcare

A new report published by an independent risk management consulting firm, Milliman, commissioned by Nice Healthcare, shows that the Nice Healthcare’s integrated healthcare model addresses services that are used by 89% of healthcare utilizers in a typical large employer commercial health benefit plan, based on a study of historical data. The data underlying the research included 58 million member months of exposure and more than $28 billion in allowed claims. “Our focus is on how we can bring better access at an affordable price to small businesses,” says Thompson Aderinkomi, CEO of Nice Healthcare. “Our model also provides support to health plans by being the first line of care enabling providers to only see the patients who need them most.” Using a mix of technology, logistics, and expert clinical care, Nice Healthcare brings a fully integrated clinic to the patient, providing in-home and virtual primary care, mental health therapy, physical therapy, and medications. The service is a direct-to-employer benefit and can help health plans avoid high-dollar claims and wasteful care. Aligned with Nice’s mission of accessible services, the study found that the services Nice can address make up the majority of healthcare costs typically incurred at urgent care facilities or via telehealth. With Nice, you can get a visit, labs, x-rays and more right in your home. Nice also offers virtual visits, giving patients quick answers to their healthcare questions without relying on insurance, networks, or scheduling around busy work days. To read the full study visit https://www.milliman.com/en/insight/Benchmarking-cost-and-utilization-of-direct-primary-care-services. Nice Healthcare is making truly integrated comprehensive healthcare accessible, allowing patients to easily get care for their everyday needs. Using a mix of technology, logistics, and expert clinical care, they bring a fully integrated clinic to you, providing in-home and virtual primary care, mental health therapy, and physical therapy. Their clinicians can also offer patients x-rays, 35 labs and blood draws and a formulary with over 550 medications with no out-of-pocket costs. Since launching in Minnesota in 2017, Nice has expanded its integrated care services to 12 states. Contact Details Nice Healthcare pr@nice.healthcare +1 586-461-2103 pr@nice.healthcare Company Website https://www.nice.healthcare/

November 10, 2022 09:00 AM Eastern Standard Time

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

BioRestorative Therapies, Inc.

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. BioRestorative’s novel drug BRTX-100, which is approved by the Food and Drug Administration (FDA) to enter Phase 2 clinical trials, targets damaged and degenerating discs. The Company is well into its trial, a 99-patient prospective, randomized, double-blinded, controlled study, the gold standard of its kind. BRTX-100 is an autologous stem cell product that uses the patient’s own stem cells, which are harvested, cultured, combined with their own autologous platelet lysate and then injected directly into the affected disc to initiate the healing and repair process. Previous human investigator-initiated studies using a similar product to BRTX-100 (but arguably less potent) have shown a reduction in pain and increase in function in excess of the stated primary endpoints in BioRestorative’s phase 2 protocol. This fascinating opportunity presents a study that is highly suggestive of the potential outcomes for which they are currently processing. In addition, the treatment is anticipated to be safer, cheaper and more effective with a single treatment. BioRestorative’s other product — ThermoStem — has highly promising results in the treatment of obesity and related diseases. Obesity affects over 40% of Americans, and BioRestorative is developing a novel stem-cell population — brown adipose tissue — that shows signs of regulating metabolic activity and reducing excess fat. BioRestorative Therapies Has Joined The Leagues Of 23andMe, Qualcomm and Naviscan In September 2021, BioRestorative was awarded a Small Business Technology Transfer (STTR) phase I grant for $256,000. The project seeks to evaluate the therapeutic effects on the company’s hypoxic cultured bone marrow derived mesenchymal stem cells (BRTX-100) after encapsulation with a PEG-peptide hydrogel. The work is being done in collaboration with Dr. Lori Setton, Chair of the Department of Biomedical Engineering at Washington University in St. Louis. SBIR is a federal program coordinated by the Small Business Administration that funds research and development. STTR is a Small Business Innovation Research (SBIR) sister program. The programs are one of the largest sources of funding for early-stage companies. Big-name companies like 23andMe Holding Co. (NASDAQ: ME), Qualcomm Inc. (NASDAQ: QCOM) and Naviscan Inc. were awarded SBIR and STTR funding, which helped them become the companies they are today. SBIR and STTR programs are highly competitive programs that foster and encourage small businesses to engage in Federal Research/Research and Development (R/R&D) with the potential for product commercialization. Through this highly competitive awards-based program, SBIR and STTR enable small businesses to explore their technological potential and provide the incentive to profit from its commercialization. SBIR and STTR are like gold mines for smaller companies. Borrowing from a bank is often difficult for new, innovative businesses because they lack collateral and revenue to help secure loans. While venture capital often fills the gap, it’s not always available and companies can lose autonomy if a venture capital firm wants to have a heavier hand in decisions. With the SBIR and STTR programs, funding is stable and predictable as it is an award, not a loan. Small businesses retain intellectual property rights. Additionally, the National Institute of Health (NIH), which oversees the programs, provides recognition, validation and visibility to early-stage companies that they might not otherwise have with either a loan from a bank or venture capital. Receiving an SBIR and STTR award can also help attract more funding because of the prestige associated with the programs. SBIR and STTR programs have supported the development of 99 drugs from 1996-2020. Of these drugs, 16% of all treatments made a “significant” advance over available medicines. Companies that receive SBIR and STTR awards are put on the map and can credibly say they were backed by the NIH. With the recent grants BioRestorative Therapies has received, the NIH has given the company a stamp of approval. To learn more about BioRestorative Therapies, visit its website. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

November 10, 2022 08:00 AM Eastern Standard Time

Airly secures new $5.5M funding round to fight air pollution and save lives

Airly

Air pollution is the most-pressing environmental health crisis of our time with approximately nine in 10 people around the world breathing unclean air. Helping to spotlight this existential threat, cleantech startup Airly is today announcing a $5.5M series A funding round as it targets cleaning the air by understanding the exact sources based on sensor data and comprehensive actionable insights. The funding round was led by firstminute capital and Pi Labs with participation from existing investors including. Sir Richard Branson Family Office, AENU, Untitled and new investors including Slack co-founder Cal Henderson, Snowflake co-founder Marcin Zukowski as well as institutional investors Semapa Next and TO Ventures. With this funding round, Airly has raised $8.8M from investors since March 2021, as it now scales to realize the potential of its complete air quality monitoring platform and supporting local governments determined to fight for clean air with an end-to-end solution. The Airly platform provides solutions for air quality monitoring to local governments, companies and local communities in over 40 countries. They use sensors to observe data and now Airly will be able to provide a complete dashboard enabling users to go one step further. They will be able to monitor the data and obtain actionable insights that will translate into effective actions to improve air quality and understand their impact on health and well-being. The dashboard will offer multiple features including a report generator, insights, impact tracker and the city ranking. Wiktor Warchałowski, CEO and co-founder of Airly commented: “With the funding round we are going deeper with our users. Monitoring with our sensors has helped bring the issue to the surface and now with our dashboard offering actionable insights and nudges, we believe this will be the catalyst that helps move measures and policies into place to repair the air we breathe.” Recently, Airly launched the largest air quality monitoring network in a European city by installing 165 sensors in Warsaw. Similarly large networks have also been launched in the UK (Birmingham and the London boroughs of Lambeth, Haringey and soon Southwark) and Indonesia (Jakarta). Airly has also strategic partnerships with the likes of JCDecaux, NHS, NILU (Norwegian Institute for Air Research) and is a key partner in the European Union’s Horizon 2020 funded DivAirCity project. Airly impact studies have proven that cities with a dense network of air quality sensors are achieving faster reduction in air pollution. Since 2019, four cities from the C40 group (a global network of cities taking urgent action to confront the climate crisis) with dense monitoring networks (Jakarta, Lisbon, London and Warsaw) have improved their overall air quality by 16% (compared to 5% improvement made by cities without dense networks). “ Trailblazers in London are showing how real-time local air quality data is the catalyst for taking action to make our urban spaces healthier and more sustainable. I expect many cities and local authorities to follow their leadership, starting with more precise and local data. Airly is at the forefront of building this data infrastructure and our fight against air pollution, and we’re very proud to continue our support by co-leading their Series A” - says Brent Hoberman, co-founder and Executive Chairman of Founders Forum and firstminute capital. More than 10 million people die each year from air pollution. Exposure to air pollution increases the risk of stroke, dementia, heart disease, lung cancer and chronic respiratory diseases, with children particularly vulnerable. Last year, the World Health Organization tightened up on safe levels of air pollutants. Airly is the first platform worldwide to include the new index in its analytical tools and free-to-use community tools (incl. mobile app and web application). Stefania Ponzo, Partner at Pi Labs, commented: “ The ways in which towns and cities contribute to our health and wellbeing will shape how we live for years to come – and air quality plays a huge part in that. We believe Airly’s solution will become an essential tool in cities around the world, helping to improve liveability standards, reduce emissions, and ultimately, getting us closer to sustainability and wellness goals. We are excited at the prospect of partnering with a team that can truly go global with its impact.” About Airly Airly offers a comprehensive SaaS solution for air quality monitoring and control. It is possible by a proprietary low-cost distributed sensor network delivering hyper-local real-time air quality data. Airly provides governments, enterprises and communities decision-ready data on air quality. Airly enables organisations to monitor air quality, analyse trends and sources, develop targeted initiatives to combat pollution, and track improvements. Thanks to that, they’re supporting organisations in their journey to eliminate pollution, improve air quality and protect public health. Airly recently won a number of landmark public tenders such as London’s Borough Lambeth, Birmingham and one of Europe’s largest contracts with the City of Warsaw. Airly can build on a significant and ever growing customer base comprising over 600 local authorities. The company also cooperates with global brands such as JC Decaux, Bolt, E-on, Philips, Skanska and Veolia. For more information visit www.airly.org Contact Details Airly Marcin Gnat +48 507 416 727 m.gnat@airly.org Company Website https://airly.org/en/

November 10, 2022 07:00 AM Eastern Standard Time

Image

UNOS Seeks New CEO to Be Voice for Diverse Needs of Donation and Transplant Community

United Network for Organ Sharing

United Network for Organ Sharing (UNOS) is conducting a national search for a permanent Chief Executive Officer. UNOS is the engine that powers the nation’s organ donation and transplant system under contract with the federal government. UNOS is seeking their next CEO, who will work collaboratively with the donation and transplant community, federal partners, Congress, and others to pursue projects and initiatives that build on ongoing successes while confronting the challenges facing the nation’s organ donation and transplant system. This includes leading the organization into a future, focusing on patient engagement, equity, innovation and driving increases in lifesaving transplants. The national search process is being conducted by a search committee at the direction of the UNOS Board of Directors and facilitated by Spencer Stuart, a global leader in executive searches with decades of experience. The Health Resources and Services Administration (HRSA) has also been involved in the process and will continue to provide feedback, as will members of the wider donation and transplant community. “We are committed to ensuring that all players in the system – patients, professionals and everyone else involved in our lifesaving mission – are represented in this process,” said Jerry McCauley, M.D., the President of the UNOS Board and the head of the candidate search committee. “We want to make sure that we’re inviting voices from different communities, experiences, and perspectives, and substantively incorporating that feedback into our process.” Maureen McBride, Ph.D. is currently serving as Interim CEO of UNOS and remains committed to focusing on continued system-wide advancement, including patient engagement and empowerment; advocating for holistic, evidence-based, patient-centered policy solutions at the federal level; and maximizing opportunities to better support research into equitable access to care. UNOS sought anonymous feedback from nearly 100 individuals to develop a representative candidate profile. These individuals are all actively engaged in the donation and transplant community, have experience in governance roles and have relevant knowledge of current issues and challenges facing the national system. These individuals also represented a broad spectrum of the donation and transplant community, covering an array of expertise, areas of involvement, backgrounds and perspectives and included patients, physicians, professionals, advocates and others. UNOS looks forward to completing the process and announcing the new CEO in the spring of 2023. “We have welcomed and will continue to welcome any and all ideas and feedback from members of the donation and transplant system,” McCauley said. “This inclusive process will result in a chosen candidate who is eager to lead a national organization of more than 400 employees, successfully compete for the next OPTN contract, convene the community, collaborate with partners at all levels and reach across barriers to drive continuous improvement.” About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

November 09, 2022 03:24 PM Eastern Standard Time

Poolbeg Pharma makes virus "breakthrough" using AI drug discovery technology

Poolbeg Pharma PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 09, 2022 08:51 AM Eastern Standard Time

Video

1 ... 192 193 194 195 196 ... 307